Latest News View All
Featured Interview: The End of the Undruggable
Targeted protein degradation (TPD) therapy is a promising new class of targeted treatments to combat cancers and other conditions. In a recent feature by STAT,...
Continue ReadingIntroducing WuXi AppTec’s NMR-based FBDD Platform
NMR is a benchmark tool for fragment-based drug design, offering quantitative binding data and detailed structural insights on target proteins. We are excited to introduce...
Continue ReadingIntegrated Direct-to-Biology (D2B) Platform
Looking for a solution to accelerate your drug discovery processes? Introducing WuXi AppTec’s Integrated Direct-to-Biology (D2B) platform—a cost-effective and time-saving approach that empowers small molecule...
Continue ReadingUpcoming EventsView All
September 21, 2025 - September 24, 2025
Cambridge, UK
Fragment-Based Lead Discovery Conference
Learn More
